报价延迟最少15分钟:2026/04/15 09:30 EDT
常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
25.09 
|
|
|
| 价值评估 |
|
盈利(现时/预测)
-0.13/0.83
|
|
企业价值
3.23B
|
| 资产负债 |
|
每股账面净值
1.53
|
| 现金流量 |
|
现金流量率
--
|
| 损益表 |
|
收益
376.07M
|
|
每股收益
0.40
|
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
同行比较之报价最少15分钟延迟 (夜盘时段除外)
|
业务概览
|
|||
| Arcutis Biotherapeutics Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing treatments for dermatological diseases with high unmet medical needs. Its current portfolio is comprised of differentiated topical and systemic treatments with potential to treat immune-mediated dermatological diseases and conditions. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population. The Company has one reportable segment relating to the development and commercialization of treatments for dermatological diseases. |
